Biofilm Eradication Four-Step Strategy: Study of Using Self-Assembled Azithromycin/Rhamnolipid Nanoparticles for Removing Pseudomonas aeruginosa Biofilm

DONG Ya-ting, LI Peng-yu, SUN Ying-ying, RAO Yi-qin, YU Shi-hui, HU Hai-yan

Abstract

To investigate the in vitro eradicative effect of self-assembled azithromycin/rhamnolipid nanoparticles (AZI-RHL NPs) on Pseudomonas aeruginosa (P. aeruginosa) biofilm.  Methods  AZI-RHL NPs were prepared and characterized. The minimum inhibitory concentration (MIC) of AZI-RHL NPs on planktonic P. aeruginosa was measured by the broth microdilution method. The eradicative effect of AZI-RHL NPs on P. aeruginosa biofilm was evaluated via crystal violet staining and SYTO 9/PI live/dead staining. Fluorescence labeling was used to measure the eradicative effect of NPs on extracellular polymeric substances (EPS). In addition, crystal violet staining was performed to evaluate the inhibitory effect of AZI-RHL NPs on the adhesion of P. aeruginosa on human bronchial epithelial BEAS-2B cells. To investigate the ability of AZI-RHL NPs to penetrate mucus, the interaction between NPs and mucin was measured via particle size changes after co-incubation with mucin solution.  Results  The AZI-RHL NPs had a particle size of about 121 nm and were negatively charged on the surface, displaying a high encapsulation efficiency and a high drug loading capacity of 96.72% and 45.08% for AZI, respectively and 99.38% and 53.07% for RHL, respectively. The MIC of AZI-RHL NPs on planktonic P. aeruginosa was half of that of using AZI alone. AZI-RHL NPs displayed the capacity to effectively destroy the biofilm structure and remove the proteins and polysaccharides in EPS, eradicating biofilms in addition to reducing the survival rate of bacteria in the biofilm. AZI-RHL NPs were shown to have inhibited P. aeruginosa adhesion on BEAS-2B cells and prevented the residual bacteria from forming a new biofilm. There was no significant change in the particle size of NPs after co-incubation with mucin solution, indicating a weak interaction between NPs and mucin, and suggesting that NPs could penetrate the mucus and reach the P. aeruginosa infection sites.  Conclusion  AZI-RHL NPs were able to effectively enhance the removal of P. aeruginosa biofilm through a four-step strategy of biofilm eradication, including penetrating the mucus, disintegrating the biofilm structure, killing the bacteria dispersed from biofilm, and preventing the adhesion of residual bacteria. We hope that this study will provide a replicable common strategy for the treatment of refractory infections caused by P. aeruginosa and other types of biofilms.

 

Keywords: Azithromycin, Rhamnolipid, Self-assembled nanoparticles, Pseudomonas aeruginosa, Antibiofilm

 

Full Text:

PDF


References


PANG Z， RAUDONIS R， GLICK B R， et al. Antibiotic resistance in Pseudomonas aeruginosa: Mechanisms and alternative therapeutic strategies. Biotechnol Adv，2019，37(1): 177–192.

MALHOTRA S， HAYES D J， WOZNIAK D J. Cystic fibrosis and Pseudomonas aeruginosa: The host-microbe interface. Clin Microbiol Rev， 2019， 32(3): e00138-18[2021-05-28]. https://pubmed.ncbi.nlm.nih.gov/311 42499/. doi: 10.1128/CMR.00138-18.

BASSETTI M， VENA A， CROXATTO A， et al. How to manage Pseudomonas aeruginosa infections. Drugs Context，2018，7: 212527[2021-05-28]. https://doi.org/10.7573/dic.212527.

DOULL I. Cystic fibrosis 2019: Year in review. Paediatr Respir Rev，2020， 35: 95–98[2021-05-28]. https://doi.org/10.1016/j.prrv.2020.04.001.

HUBBLE V B， HUBBARD B A， MINROVIC B M， et al. Using small-molecule adjuvants to repurpose azithromycin for use against Pseudomonas aeruginosa. ACS Infect Dis，2019，5(1): 141–151.

WAN F， BOHR S S， KLODZINSKA S N， et al. Ultrasmall TPGS-PLGA hybrid nanoparticles for site-specific delivery of antibiotics into Pseudomonas aeruginosa biofilms in lungs. ACS Appl Mater Interfaces， 2020，12(1): 380–389.

HUANG Z， ZHOU T， YUAN Y， et al. Synthesis of carbon quantum dot-poly lactic-co-glycolic acid hybrid nanoparticles for chemo-photothermal therapy against bacterial biofilms. J Colloid Interface Sci， 2020，577: 66–74[2021-05-28]. https://doi.org/10.1016/j.jcis.2020.05.067.

SHEN Y， ZOU Y， CHEN X， et al. Antibacterial self-assembled nanodrugs composed of berberine derivatives and rhamnolipids against Helicobacter pylori. J Control Release，2020，328: 575–586[2021-05-28]. https://doi.org/10.1016/j.jconrel.2020.09.025.

LI P， CHEN X， SHEN Y， et al. Mucus penetration enhanced lipid polymer nanoparticles improve the eradication rate of Helicobacter pylori biofilm. J Control Release，2019，300: 52–63[2021-05-28]. https://doi.org/10.1016/j.jconrel.2019.02.039.

BELANGER C R， LEE A H， PLETZER D， et al. Identification of novel targets of azithromycin activity against Pseudomonas aeruginosa grown in physiologically relevant media. Proc Natl Acad Sci U S A，2020，117(52): 33519–33529.

KAISER S J， MUTTERS N T， BLESSING B， et al. Natural isothiocyanates express antimicrobial activity against developing and mature biofilms of Pseudomonas aeruginosa. Fitoterapia，2017，119: 57–63[2021-05-28]. https://doi.org/10.1016/j.fitote.2017.04.006.

DE OLIVEIRA D， FORDE B M， KIDD T J， et al. Antimicrobial resistance in ESKAPE pathogens. Clin Microbiol Rev， 2020， 33(3): e00181-19[2021-05-28]. https://pubmed.ncbi.nlm.nih.gov/32404435/. doi: 10.1128/CMR.00181-19.

OLIVARES E， BADEL-BERCHOUX S， PROVOT C， et al. Clinical impact of antibiotics for the treatment of Pseudomonas aeruginosa biofilm infections. Front Microbiol，2019，10: 2894[2021-05-28]. https://doi.org/10.3389/fmicb.2019.02894.

CIOFU O， TOLKER-NIELSEN T. Tolerance and resistance of Pseudomonas aeruginosa biofilms to antimicrobial agents—How P. aeruginosa can escape antibiotics. Front Microbiol，2019，10: 913[2021-05-28]. https://doi.org/10.3389/fmicb.2019.00913.

SHEN Y， LI P， CHEN X， et al. Activity of sodium lauryl sulfate, rhamnolipids, and N-acetylcysteine against biofilms of five common pathogens. Microb Drug Resist，2020，26(3): 290–299.

THI M， WIBOWO D， REHM B. Pseudomonas aeruginosa biofilms. Int J Mol Sci， 2020， 21(22): 671[2021-05-28]. https://doi.org/10.3390/ijms 21228671.

LILLEHOJ E P， GUANG W， HYUN S W， et al. Neuraminidase 1-mediated desialylation of the mucin 1 ectodomain releases a decoy receptor that protects against Pseudomonas aeruginosa lung infection. J Biol Chem，2019，294(2): 662–678.

GUILHEN C， FORESTIER C， BALESTRINO D. Biofilm dispersal: Multiple elaborate strategies for dissemination of bacteria with unique properties. Mol Microbiol，2017，105(2): 188–210.

TURCIOS N L. Cystic fibrosis lung disease: An overview. Respir Care， 2020，65(2): 233–251.

ZIERDEN H C， JOSYULA A， SHAPIRO R L， et al. Avoiding a sticky situation: Bypassing the mucus barrier for improved local drug delivery. Trends Mol Med，2021，27(5): 436–450.


Refbacks

  • There are currently no refbacks.